<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509665</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000558049</org_study_id>
    <secondary_id>MUSC-100838</secondary_id>
    <nct_id>NCT00509665</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer</brief_title>
  <official_title>A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving gemcitabine together with
      doxorubicin works in treating patients with recurrent or progressive head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Every 6 weeks from the time of initial treatment for up to 8 months</time_frame>
    <description>Per Response Evaluation Criteria in Solid Tumors (RECIST) for target lesions assessed by CT or MRI: Complete Response (CR) is the disappearance of all target lesions (TL) and non-target lesions (NTL); Partial Response (PR) is defined by either a CR of TL and stable disease (SD) in NTL or PR of TL and non-progressive disease (PD) in NTL. Response rate is the sum of CR + PR as defined above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Every 6 weeks for up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Through the end of follow up, for an average of 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the time of initial therapy until the time of death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Had Greater Than Grade 2 Toxicity</measure>
    <time_frame>from time of initial treatment until end of study, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Cytoxocity With Cell-cycle Arrest</measure>
    <time_frame>prior to first dose of drug and every 6 weeks up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Cytotoxicity With Apoptosis in Cancer Cells</measure>
    <time_frame>prior to first dose of drug and every 6 weeks for up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine+doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.</description>
    <arm_group_label>Gemcitabine+doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
    <arm_group_label>Gemcitabine+doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically or cytologically confirmed head and neck cancer

               -  Recurrent or progressive disease

          -  Must have measurable disease, defined as at least one lesion that can be accurately
             measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm by
             conventional techniques or as ≥ 10 mm by spiral CT scan

          -  Must have received prior platinum-based chemotherapy regimen (cisplatin or
             carboplatin) with or without radiotherapy, unless the patient was deemed unsuitable
             for platinum-based therapy due to renal dysfunction or other clinical contraindication

        Exclusion criteria:

          -  Known brain metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status (PS) ≤ 2 OR Karnofsky PS ≥ 60%

          -  Absolute neutrophil count ≥ 1,500/μL

          -  Platelets ≥ 100,000/µL

          -  Total bilirubin ≤ 1.5 mg/dL

          -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal

          -  Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 30 mL/min

          -  Females of reproductive potential must not plan on conceiving children during study
             treatment period and must agree to use adequate contraception (hormonal or barrier
             method of birth control or abstinence) prior to study entry and for the duration of
             the study

        Exclusion criteria:

          -  Not pregnant or breastfeeding

          -  History of allergic reaction attributed to compounds of similar chemical or biological
             composition to gemcitabine hydrochloride or doxorubicin hydrochloride

          -  Lower than normal cardiac ejection fraction

               -  Patients must have an echocardiogram or MUGA scan prior to the use of study drugs

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements
             including, but not limited to, any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situation

          -  Clinical AIDS or known positive HIV serology

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  Recovered from prior therapy

          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

          -  At least 30 days since prior experimental agents

          -  At least 4 weeks since prior radiotherapy for palliation or for the primary tumor

        Exclusion criteria:

          -  Prior gemcitabine hydrochloride or doxorubicin hydrochloride

          -  Concurrent hormones or other chemotherapeutic agents, except for steroids given for
             adrenal failure, hormones given for non-disease-related conditions (e.g., insulin for
             diabetes), or intermittent use of dexamethasone as an antiemetic

          -  Concurrent palliative radiotherapy

          -  Other concurrent investigational or commercial agents or therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul O'Brien</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15;17(18):6097-105. doi: 10.1158/1078-0432.CCR-11-0930. Epub 2011 Jul 26.</citation>
    <PMID>21791630</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine+Doxorubicin</title>
          <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine+Doxorubicin</title>
          <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="45" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Per Response Evaluation Criteria in Solid Tumors (RECIST) for target lesions assessed by CT or MRI: Complete Response (CR) is the disappearance of all target lesions (TL) and non-target lesions (NTL); Partial Response (PR) is defined by either a CR of TL and stable disease (SD) in NTL or PR of TL and non-progressive disease (PD) in NTL. Response rate is the sum of CR + PR as defined above.</description>
        <time_frame>Every 6 weeks from the time of initial treatment for up to 8 months</time_frame>
        <population>patients who were on study at the time of response assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Per Response Evaluation Criteria in Solid Tumors (RECIST) for target lesions assessed by CT or MRI: Complete Response (CR) is the disappearance of all target lesions (TL) and non-target lesions (NTL); Partial Response (PR) is defined by either a CR of TL and stable disease (SD) in NTL or PR of TL and non-progressive disease (PD) in NTL. Response rate is the sum of CR + PR as defined above.</description>
          <population>patients who were on study at the time of response assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>Every 6 weeks for up to 8 months</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Through the end of follow up, for an average of 8 months</time_frame>
        <population>Only patients who had re-staging scans are included in the number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Only patients who had re-staging scans are included in the number of participants analyzed.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From the time of initial therapy until the time of death.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.8" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Had Greater Than Grade 2 Toxicity</title>
        <time_frame>from time of initial treatment until end of study, an average of 6 months</time_frame>
        <population>Patients who were treated on study and had greater than grade 2 toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had Greater Than Grade 2 Toxicity</title>
          <population>Patients who were treated on study and had greater than grade 2 toxicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Cytoxocity With Cell-cycle Arrest</title>
        <time_frame>prior to first dose of drug and every 6 weeks up to 6 months</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Cytoxocity With Cell-cycle Arrest</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Cytotoxicity With Apoptosis in Cancer Cells</title>
        <time_frame>prior to first dose of drug and every 6 weeks for up to 6 months</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine+Doxorubicin</title>
            <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Cytotoxicity With Apoptosis in Cancer Cells</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Prior to each cycle while on treatment for an average of 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine+Doxorubicin</title>
          <description>doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Anderton</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2708</phone>
      <email>anderton@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

